Answers are grounded in this paper and cite their sources.
Tumor recurrence remains the predominant cause of mortality in patients with glioblastoma (GBM), and (chemo/radio‐) therapy‐induced senescence (TIS) has recently been recognized as a key driver by deteriorating the post‐surgical microenvironment. To exploit this “senescence trap”, we developed an injectable, bacterial cellulose (BC)‐based hydrogel system (ABT@Gal‐gel) designed for preferential elimination of senescent GBM cells. This platform encapsulates galactose‐modified polydopamine nanoparticles loaded with the senolytic agent ABT‐263 (ABT@Gal‐PDA). It enables programmed, β‐galactosidase (β‐Gal)‐responsive drug release to preferentially eliminate pro‐tumorigenic senescent cells. Moreover, the cellulose and chitosan in the hydrogel further remodel the immunosuppressive tumor microenvironment by inducing M1 macrophage polarization. In orthotopic GBM mouse models, this dual‐functional strategy significantly inhibits tumor recurrence and prolongs overall survival. Overall, this study presents a novel strategy by coupling senescence‐associated intracellular targeting with tumor‐associated macrophage (TAM) repolarization to suppress GBM relapses, providing a promising direction for the next generation of postoperative brain cancer therapies.
No takes yet. Share an insight, caveat, or question.
Ning et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: